Congenital deficiency of the purine metabolic enzyme ADA causes severe combined immunodeficiency (SCID). The profound T lymphopenia characteristic of this disease has limited direct investigation of ...

Please provide your email address to receive an email when new articles are posted on . T-receptor excision circle screenings can miss cases of adenosine deaminase deficiency (ADA), which can be fatal ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Leadiant Biosciences, Inc. today announced that the Food and Drug Administration (FDA) has granted approval to Revcovi™ (elapegademase-lvlr) injection in the U.S.

Please provide your email address to receive an email when new articles are posted on . Including tandem mass spectroscopy in newborn screenings to identify adenosine deaminase deficiencies could save ...

Overall and event-free survival of 100 and 95%, respectively, seen with autologous CD34+ hematopoietic stem-cell lentiviral gene therapy. HealthDay News — Autologous CD34+ hematopoietic stem-cell ...

Congenital adenosine deaminase (ADA) deficiency results in a severe combined immunodeficiency, but the precise molecular mechanism triggered by ADA deficiency had remained unclear. In August 1 Journal ...

ADA-SCID, or severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency, affects about 15 children each year in Europe. A child born with ADA-SCID is unable to fight off everyday ...

Following a positive opinion from the EMA, the transfer of marketing authorization of Strimvelis from Orchard Therapeutics has been approved by the European Commission Fondazione Telethon will now be ...